Home › Healthcare › Resonance Health (ASX:RHT)

Resonance Health funds three growth bets after a profitable FY26

Healthcare By Ada Torres 5 min read

Resonance Health delivered a $1.5 million profit and positive operating cash flow in every quarter of FY26, while raising $6 million to accelerate three growth programmes. The challenge is replacing a MASH trial that generated 48% of last year’s revenue.

  • FY26 revenue rose 42% to $15.8 million
  • Net profit reached $1.5 million after a $1.7 million loss
  • Oversubscribed $6 million placement funded obesity endpoints, TrialsWest expansion and fibrosis-device development
  • FY27 guidance is $17 million to $22 million revenue and $2.6 million to $3.6 million normalised EBITDA
  • The major MASH trial is due to finish in early 2027

Profitability arrives as Resonance prepares for its largest revenue gap

Resonance Health Limited (ASX:RHT) has reached the point many small healthcare companies spend years promising: growth paid for itself. Revenue climbed 42% to $15.8 million in FY26, net profit after tax swung to $1.5 million from a $1.7 million loss, and operating cash flow stayed positive in all four quarters.

Customer receipts reached a record $14.3 million, while operating cash flow was $2.9 million. Resonance finished the year with $4.8 million in cash against $2.5 million of debt, compared with net cash of roughly $100,000 a year earlier. Employee costs also fell from 51% of revenue to 41%, helping normalised EBITDA reach the upgraded target of $2.6 million.

A $6 million placement backs three parallel programmes

The stronger balance sheet did not stop Resonance from raising capital. An oversubscribed placement issued 83 million new shares at 7.2 cents each, creating about 15% dilution for shareholders who did not participate. The company says the decision was intended to fund opportunities that would otherwise have been pursued sequentially over several years.

The three targets are new muscle and body-composition endpoints for obesity trials, the first four of six planned TrialsWest sites on Australia’s east coast, and further development of the MRI liver fibrosis device. The raise took pro forma net cash to $7.9 million and also leaves room for potential bolt-on acquisitions within the company’s existing healthcare and imaging domains. The earlier $6 million placement was described as funding these programmes for 24 months, but the company has not included their contribution in FY27 guidance.

MASH trial concentration creates the immediate test

That caution matters because the company’s revenue base remains concentrated. A major MASH clinical trial accounted for 48% of FY26 revenue and is expected to finish in early calendar 2027. Recruitment was slower than planned and screening failures forced a budget reset in June, reducing the margin Resonance expects to earn, although milestone invoicing continues into the current year.

Management says multiple CRO opportunities are under review and its SaMD order and tender pipeline exceeds $13 million. The company’s completed MASH trial recruitment provides an established base for the clinical-trials business, but replacing the departing revenue will require opportunities to become signed contracts rather than remain pipeline language.

Fibrosis device remains promising, preliminary and outside guidance

The most consequential development project is Resonance’s investigational MRI liver fibrosis device. In a preliminary analysis of 50 biopsy-verified patients, the device recorded an AUROC of 0.82 for significant fibrosis and 0.79 for advanced fibrosis. Management compared the first result with the published figure for FibroScan, while acknowledging a gap against MR elastography on advanced fibrosis.

The figures are not regulatory clearance or a commercial product. Resonance still has to refine the model, agree a validation design with the US FDA, build further data through paid investigational use and eventually conduct a pivotal study. The company’s preliminary fibrosis results came from a small early dataset, and the remaining cohort and future validation work could change the picture.

FY27 guidance leaves expansion upside uncounted

Resonance is guiding to FY27 revenue of $17 million to $22 million and normalised EBITDA of $2.6 million to $3.6 million. The range assumes existing contracted trials run their course, modest pipeline wins and continued SaMD conversion, but excludes the fibrosis device, acquisitions, new TrialsWest sites and geographic expansion.

It has also completed design and testing of an MRI muscle volume and quality endpoint intended for GLP-1 and obesity studies, although verification, validation and quality-system documentation must still be completed before it is offered as an investigational endpoint. Meanwhile, the company expects to refinance its $2.5 million bank facility before it matures in March 2027.

The next evidence will come from execution, not ambition

Resonance’s address set an ambitious longer-term target of $50 million in revenue by the end of FY28, with acquisitions expected to bridge the gap between an organic path toward $30 million and that goal. For now, the more immediate scorecard is narrower: replace the MASH revenue, convert the SaMD pipeline, open the east-coast sites and advance the fibrosis programme without allowing the new capital to outrun the company’s operating discipline.

Bottom Line?

The balance sheet now gives Resonance room to move, but FY27 will show whether its pipeline can replace the MASH trial before the revenue gap opens.

Questions in the middle?

  • How much of the more than $13 million SaMD pipeline will convert into signed work before the MASH trial finishes?
  • Can the new east-coast TrialsWest sites reach planned opening and profitability milestones without diluting the performance of the existing network?
  • Will further fibrosis data close the gap on advanced disease and support a credible path towards FDA validation?

Sources